anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Kenalog
Trial phase: Phase 4
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.

Triamcinolone Acetonide 10 mg/mL: 10 mg/mL intralesional injection
Eligibility criteria:
Inclusion Criteria:

At least 18 years of age
Diagnosed with nail psoriasis in at least 2 fingernails
Willing to give written informed consent and able to adhere to procedures and visit schedules
Must consent to having the fingernails photographed during the study period

Exclusion Criteria:

Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study. This is including, but not limited to: immunodeficiency, onychomycosis, any other nail condition other than psoriasis, allergy to triamcinolone acetonide, local anesthetic, normal saline, or any other material used for procedures
Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of study, and/or oral corticosteroids for >1 month within the 6 months of study (exception: inhaled steroids)
Subject known to have received treatment with investigational drugs or devices within 30 days prior to enrollment into this study
Subject who is unwilling to abstain from any cosmetic nail treatments outside those provided by the study clinic, beyond basic nail trimming (i.e. no spa nail treatments, no nail polish use, no other topical prescription nail medication)
Subject who is unwilling to abstain from any medical nail treatments on their nails other than the study intervention (i.e. topical steroids, anti-fungal creams) for the duration of the study intervention and for duration of the washout period (if applicable)
Subject who is part of the staff personnel directly involved with this study or a family member of the investigational study staff
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: 1 ml 0.5% isobaric bupivacaine (5 mg) + 15 mcg fentanyl intrathecal plus epidural volume extension (EVE)

Bupivacaine: 1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
Eligibility criteria:
Inclusion Criteria:

Any patient scheduled for a postpartum tubal ligation at the Women and Infants Center will be eligible for the study

Exclusion Criteria:

age less than 18 years old
allergy to either local anesthetic class (amide or ester)
contraindication to spinal anesthesia
Intervention: Chloroprocaine
Trial phase: Phase 2
ATC code: N01BA04
SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1Cl
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: 5 ml 1% spinal chloroprocaine (50 mg) intrathecal plus epidural volume extension (EVE)

Chloroprocaine: Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
Eligibility criteria:
Inclusion Criteria:

Any patient scheduled for a postpartum tubal ligation at the Women and Infants Center will be eligible for the study

Exclusion Criteria:

age less than 18 years old
allergy to either local anesthetic class (amide or ester)
contraindication to spinal anesthesia
Intervention: Citalopram
Trial phase: Phase 4
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants with CRP<1 will be prescribed escitalopram

Escitalopram: Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
Eligibility criteria:
Inclusion Criteria:

Women and men ages 18-65
Current diagnosis of Major Depressive Disorder
Able to read, speak, and understand English

Exclusion Criteria:

Antidepressant use within the last 8 weeks
Active infection or uncontrolled autoimmune disease
Currently on oral corticosteroids or active immune suppressive therapy (methotrexate, cyclosporine, anti-cytokines medications, etc).
Current diagnosis of uncontrolled HIV, hepatitis C or significant immunodeficiency
Alcohol or substance use disorder
Positive urine drug test for illicit substances or substances used out of the context of prescription
Cognitively unable to give informed consent
Pregnant or breastfeeding women, women of childbearing potential who are not using an accepted means of birth control, or women with a positive urine pregnancy test
History of seizure disorder
Previous significant adverse reaction to escitalopram or bupropion
History of non-response to adequate doses of escitalopram or bupropion XL
Current use of concomitant psychotropic agents (anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, folate, l-methylfolate, s-adenosyl methionine, lithium) not on the same dose for at least four weeks prior to study entry or who do not agree to continue at the same dose during the acute phase of the study.
Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder
Current anorexia nervosa or bulimia nervosa
Suicidal ideation of the degree that, in the opinion of the evaluating clinician, participation in the study would place them at significantly increased risk of suicide
Unstable medical issues of such degree that, in the opinion of the evaluating clinician, participation in the study would place them at significant risk of a serious adverse event
Intervention: Bupropion
Trial phase: Phase 4
ATC code: A08AA62 | N06AX12
SMILES: CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants with CRP> or equal to 1 will be prescribed bupropion XL

Bupropion: Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
Eligibility criteria:
Inclusion Criteria:

Women and men ages 18-65
Current diagnosis of Major Depressive Disorder
Able to read, speak, and understand English

Exclusion Criteria:

Antidepressant use within the last 8 weeks
Active infection or uncontrolled autoimmune disease
Currently on oral corticosteroids or active immune suppressive therapy (methotrexate, cyclosporine, anti-cytokines medications, etc).
Current diagnosis of uncontrolled HIV, hepatitis C or significant immunodeficiency
Alcohol or substance use disorder
Positive urine drug test for illicit substances or substances used out of the context of prescription
Cognitively unable to give informed consent
Pregnant or breastfeeding women, women of childbearing potential who are not using an accepted means of birth control, or women with a positive urine pregnancy test
History of seizure disorder
Previous significant adverse reaction to escitalopram or bupropion
History of non-response to adequate doses of escitalopram or bupropion XL
Current use of concomitant psychotropic agents (anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, folate, l-methylfolate, s-adenosyl methionine, lithium) not on the same dose for at least four weeks prior to study entry or who do not agree to continue at the same dose during the acute phase of the study.
Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder
Current anorexia nervosa or bulimia nervosa
Suicidal ideation of the degree that, in the opinion of the evaluating clinician, participation in the study would place them at significantly increased risk of suicide
Unstable medical issues of such degree that, in the opinion of the evaluating clinician, participation in the study would place them at significant risk of a serious adverse event
Intervention: Citalopram
Trial phase: Phase 4
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants with CRP> or equal to 1 will be prescribed escitalopram

Escitalopram: Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
Eligibility criteria:
Inclusion Criteria:

Women and men ages 18-65
Current diagnosis of Major Depressive Disorder
Able to read, speak, and understand English

Exclusion Criteria:

Antidepressant use within the last 8 weeks
Active infection or uncontrolled autoimmune disease
Currently on oral corticosteroids or active immune suppressive therapy (methotrexate, cyclosporine, anti-cytokines medications, etc).
Current diagnosis of uncontrolled HIV, hepatitis C or significant immunodeficiency
Alcohol or substance use disorder
Positive urine drug test for illicit substances or substances used out of the context of prescription
Cognitively unable to give informed consent
Pregnant or breastfeeding women, women of childbearing potential who are not using an accepted means of birth control, or women with a positive urine pregnancy test
History of seizure disorder
Previous significant adverse reaction to escitalopram or bupropion
History of non-response to adequate doses of escitalopram or bupropion XL
Current use of concomitant psychotropic agents (anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, folate, l-methylfolate, s-adenosyl methionine, lithium) not on the same dose for at least four weeks prior to study entry or who do not agree to continue at the same dose during the acute phase of the study.
Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder
Current anorexia nervosa or bulimia nervosa
Suicidal ideation of the degree that, in the opinion of the evaluating clinician, participation in the study would place them at significantly increased risk of suicide
Unstable medical issues of such degree that, in the opinion of the evaluating clinician, participation in the study would place them at significant risk of a serious adverse event
Intervention: Mebendazole
Trial phase: Phase 2
ATC code: P02CA01 | P02CA51
SMILES: COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 197
Group description: A single 500 mg dose of the new chewable mebendazole tablets will be administered to each child in this arm.

Mebendazole: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Eligibility criteria:
Inclusion Criteria:

Male or female children aged between 3 and 12 years;
Written informed consent signed by caregiver;
Was examined by a study physician before treatment;
Provided two stool samples at baseline;
Hookworm EPG > 100 and at least two Kato-Katz thick smears slides with more than one hookworm egg;

Exclusion Criteria:

Pregnant;
Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, such as can upon initial clinical assessment;
Suffers from severe anemia (Hb < 80 g/l);
Received anthelminthic treatment or metronidazole within past four weeks.
Attending other clinical trials during the study.
Intervention: Mebendazole
Trial phase: Phase 2
ATC code: P02CA01 | P02CA51
SMILES: COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 196
Group description: A single 500 mg dose of the standard swallowable mebendazole tablets will be administered to each child in this arm.

Mebendazole: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Eligibility criteria:
Inclusion Criteria:

Male or female children aged between 3 and 12 years;
Written informed consent signed by caregiver;
Was examined by a study physician before treatment;
Provided two stool samples at baseline;
Hookworm EPG > 100 and at least two Kato-Katz thick smears slides with more than one hookworm egg;

Exclusion Criteria:

Pregnant;
Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, such as can upon initial clinical assessment;
Suffers from severe anemia (Hb < 80 g/l);
Received anthelminthic treatment or metronidazole within past four weeks.
Attending other clinical trials during the study.
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.

Remifentanil, Propofol, and Desflurane: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
Eligibility criteria:
Inclusion Criteria:

18 years of age and older
Having carotid endarterectomy surgery
Able to undergo a preoperative neurological exam

Exclusion Criteria:

Pregnant patients
Prisoners
Patients with dementia or reduced mental status acute or chronic
Known brain tumor or head trauma
Known severe, uncorrected coronary artery disease (CAD)
Ejection fraction (EF) less than 15%
Patients with intraaortic ballon pump (IABP) or other mechanical circulatory assist device
Patients with severe chronic obstructive pulmonary disease (COPD)
Combined surgical procedures (CABG and CAD)
Patients with uncontrolled or severe anxiety requiring benzodiazepine administration
Patients with history of difficult airway
Sedation other than propofol, dexmedetomidine or volatile anesthetic agent (VAA) is needed for patient (i.e. ketamine in patients with history of neuropathic pain)
Intubated or unconscious patients
Patients on methadone or fentanyl patch
Patients with known unusual or extreme anesthetic requirements
Patients who would require an unusual amount of narcotic to control pain
Patients having endarterectomy wherein surgeon requests local-regional anesthesia only
Patients with known history of prolonged emergence from anesthesia
Morbidly obese patients (BMI >40)
Patients with scalp or forehead defects that prohibit application of BIS monitor strip
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 4
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.

Remifentanil, Dexmedetomidine, and Desflurane: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
Eligibility criteria:
Inclusion Criteria:

18 years of age and older
Having carotid endarterectomy surgery
Able to undergo a preoperative neurological exam

Exclusion Criteria:

Pregnant patients
Prisoners
Patients with dementia or reduced mental status acute or chronic
Known brain tumor or head trauma
Known severe, uncorrected coronary artery disease (CAD)
Ejection fraction (EF) less than 15%
Patients with intraaortic ballon pump (IABP) or other mechanical circulatory assist device
Patients with severe chronic obstructive pulmonary disease (COPD)
Combined surgical procedures (CABG and CAD)
Patients with uncontrolled or severe anxiety requiring benzodiazepine administration
Patients with history of difficult airway
Sedation other than propofol, dexmedetomidine or volatile anesthetic agent (VAA) is needed for patient (i.e. ketamine in patients with history of neuropathic pain)
Intubated or unconscious patients
Patients on methadone or fentanyl patch
Patients with known unusual or extreme anesthetic requirements
Patients who would require an unusual amount of narcotic to control pain
Patients having endarterectomy wherein surgeon requests local-regional anesthesia only
Patients with known history of prolonged emergence from anesthesia
Morbidly obese patients (BMI >40)
Patients with scalp or forehead defects that prohibit application of BIS monitor strip
Intervention: Etrasimod
Trial phase: Phase 3
ATC code: L04AE05
SMILES: O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 238
Group description: Participants were administered one tablet of etrasimod 2 milligrams (mg) orally once daily (QD) for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
Active UC confirmed by endoscopy

Exclusion Criteria:

Severe extensive colitis
Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
Intervention: Difelikefalin
Trial phase: Phase 3
ATC code: V03AX04
SMILES: CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 222
Group description: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

CR845 0.5 mcg/kg: IV CR845 0.5 mcg/kg administered three times/week
Eligibility criteria:
Key Inclusion Criteria:

To be eligible for inclusion into the study, a patient must meet the following criteria:

Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;
Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;

Prior to Treatment:

Has completed at least 3 Worst Itching Intensity NRS questionnaires from the start of the Run-in Period up to and including the pre-dose assessment on Day 1;

Key Exclusion Criteria:

A patient will be excluded from the study if any of the following criteria are met:

Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;
Scheduled to receive a kidney transplant during the study;
New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening;
New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening;
Received another investigational drug within 30 days or five half-lives (whichever is longer) prior to the start of dosing or is planning to participate in another interventional clinical study while enrolled in this study;
Has pruritus only during the dialysis session (by patient report);
Is receiving ongoing ultraviolet B treatment and/or anticipates receiving such treatment during the study;
Participated in a previous clinical study with CR845.
Intervention: Racivir
Trial phase: Phase 4
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Daily through week 48
Eligibility criteria:
Inclusion Criteria:

Documented HIV-1 infection
Treatment naive or experienced
Self-reported illicit substance use or confirmed urine drug screen within past 6 months of any of the following: cocaine, heroin, methamphetamine, MDMA, phencyclidine, ketamine, gamma hydroxybutyrate, cathiniones, or inappropriate prescription opiate, benzodiazepine or stimulant use (excluding nicotine, alcohol, marijuana for criteria)
HIV RNA >1000 copies/mL
Creatinine clearance > 30 mL/min (Cockroft-Gault)
ALT and AST < 5 times the upper limit of normal
Willing and able to provide written informed consent

Exclusion Criteria:

History of integrase or tenofovir related HIV resistance mutations
Pregnancy
Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry
Intervention: Oraqix
Trial phase: Phase 4
SMILES: CCCNC(C)C(=O)Nc1ccccc1C.CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Participants who received 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure, either the first or second lumbar puncture included in the study.
Eligibility criteria:
Inclusion Criteria:

Pediatric cancer patients (aged 3-18) with a diagnosis of leukemia or lymphoma
Patients are expected to receive serial (i.e. > 1) LP as outpatients in Charleston Area Medical Center Children's Cancer Center in the course of 12 months for diagnostic and/or treatment purposes

Exclusion Criteria:

Patients not in the age range
Non-cancer patients
Allergy to amide anesthetics
Patients treated with class I and III anti-arrhythmic drugs (eg, amiodarone, bretylium, sotalol, dofetilide)
Patients with congenital or idiopathic methemoglobinemia
Intervention: Phentolamine Mesylate
Trial phase: Phase 2
SMILES: CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: 1 drop in each eye (QD) for one day.

Phentolamine Mesylate Ophthalmic Solution 1%: Topical Sterile Ophthalmic Solution
Eligibility criteria:
Inclusion Criteria:

Male or female patients ≥ 18 years of age
Currently experiencing severe night vision difficulty as reported subjectively
At least two patches below the normal range at any two frequencies in Contrast Sensitivity done under mesopic conditions with glare
Improvement in low contrast visual acuity (LCVA) in dim light during illumination of contralateral eye
Good general health
Written informed consent to participate in this trial
Ability to comply with all protocol mandated procedures and to attend all scheduled office visits

Exclusion Criteria:

Patients with untreated cataracts grades 1-4
Patients who wear contact lenses
Less than 5 weeks post-refractive surgery (LASIK or PRK)
Less than 5 weeks post intraocular lens insertion
Low blood pressure (systolic <120 mm Hg or diastolic <80 mm Hg)
A history of heart rate abnormalities
Administration of any investigational drug within 30 days of study initiation
Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1
Use of any systemic alpha adrenergic antagonists (Appendix 1)
Known local or systemic hypersensitivity to adrenergic antagonists
For women of childbearing potential: currently pregnant or lactating, or unwilling to use birth control during the study